Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Serum GFAP may indicate disease severity in NMOSD

Key clinical point: Serum glial fibrillary acidic protein (GFAP) may be a biomarker of disease severity and risk of attack in neuromyelitis optica spectrum disorder (NMOSD).

Major finding: Participants with elevated serum GFAP concentrations were three times more likely to have an NMOSD attack than those with lower concentrations.

Study details: A retrospective analysis of a randomized controlled trial of 230 patients with NMOSD.

Disclosures: Viela Bio, which is developing inebilizumab, and MedImmune sponsored the study. Dr. Cree has received compensation for consulting services that he provided to Alexion, Atara, Biogen, EMD Serono, Novartis, and TG Therapeutics.

Citation:

Hartung H et al. ACTRIMS 2020, Abstract P205.